vimarsana.com

Page 4 - Meaningful Improvements News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pill for Postpartum Depression Could Be Approved Next Week

A 14-day regimen of zuranolone made “meaningful improvements” for women suffering from postpartum depression during a study

New yorkUnited statesKristina deligiannidisSahar mcmahonFeinstein institutes for medical researchInstitute of behavioral scienceFeinstein institutesMedical researchAmerican journalBehavioral scienceMayo clinicPostpartum depressionDepressive symptomsMeaningful improvementsTreatment course

ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer

Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian…

First treatmentOverall survival benefitPlatinum resistant ovarian cancer comparedMeaningful improvementsProgression free survivalOverall survival observedPrior bevacizumabFurther support potentialReaking news

HARMONY BIOSCIENCES TO PRESENT NEW WAKIX® (PITOLISANT) SAFETY AND EFFICACY DATA AT SLEEP 2023 ANNUAL MEETING

Late-breaking Phase 2 proof-of-concept study in Prader-Willi syndrome accepted for poster presentation PLYMOUTH MEETING, Pa., May 10, 2023 /PRNewswire/ Harmony Biosciences Holdings, Inc. , a. | May 10, 2023

United statesKumar budurLuis sanayDrug administrationExchange commissionParagon biosciencesPrnewswire harmony biosciences holdings incLate breaking phaseBiosciences holdingsAnnual meetingAssociated professional sleep societiesChief medical officerMeaningful improvementsPooled analysisRandomized clinical trialsPresentation date

Phase 2 Results of Pitolisant in Prader-Willi Syndrome

Harmony Biosciences will present new efficacy data from a phase 2 study evaluating pitolisant in patients with Prader-Willi syndrome.

Kumar budurDrug administrationHarmony biosciences holdings incMeaningful improvementsPooled analysisRandomized clinical trialsPresentation dateBoard numberSafety resultsPlacebo controlled proofSignal detection studyPrader willi syndrome

New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life

Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in.

University of washingtonUnited statesSpring houseCraig stoltzPhilipj measeDonvitot creakyjointsTerence rooneyZismand comorbiditiesEuroqol research foundationJanssen biotech incMental healthAmerican college of rheumatologyJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonHealth qual life outcomes

vimarsana © 2020. All Rights Reserved.